No Picture
Trading Ideas

Alibaba’s Singles Day Sale Breaks Records

Singles – I am one myself – may be notorious for having their hearts broken. But on Alibaba’s 2019 Singles Day event, hearts aren’t the only thing being broken. Sales records are too and shareholders should take notice.
As the 24-hour sales event that eclipsed both Black Friday and Cyber Monday in 2018 continues to roll out, the e-commerce giant broke its own record by generating over $38 billion in sales. This, despite a slowing Chinese economy and a continuing trade war with the United States.

An E-commerce Day to Celebrate Singles
Singles Day, which is held on November eleventh (11/11) because the …read more […]

No Picture
Trading Ideas

The World Really Isn’t Going to Hell… Here’s Why

A clear-eyed view of our nation and the world is essential for successful investors.
Today, Alexander Green explains how you can filter out constant media negativity and focus on achieving a rich life.

Being a good investor starts with having a clear-eyed view of our nation and the world.
For example, those with an overly pessimistic outlook have spent years holding precious metals or cash, earning meager returns and missing the phenomenal gains available in equities.
Those with rose-tinted glasses, on the other hand, went into the Great Recession without portfolio diversification or risk mitigation – like asset allocation and trailing stops – and …read more […]

No Picture
Business News

Exclusive: Occidental seeks up to $700 million for Anadarko assets in Wyoming, Colorado – sources

Occidental Petroleum Corp is soliciting bids for oil and gas properties in Wyoming and Colorado that it acquired when it purchased Anadarko Petroleum, hoping the assets will fetch up to $700 million, according to people familiar with the matter.

…read more […]

No Picture
Trading Ideas

AstraZeneca succeeds in treating lupus in late-stage study

AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study. The results pit the British drugmaker’s anifrolumab against rival GlaxoSmithKline Plc’s Benlysta – the only new drug approved for lupus in the last 60 years. Benlysta recorded 473 million pounds of global sales in 2018, up 26% from a year earlier. …read more […]